BRS Analytical Service, a pharmaceutical testing lab, is voluntarily recalling over 75,000 cases of eye products, including various types of artificial tears, according to a U.S. Food and Drug Administration enforcement report. (Photo: Getty)
Artificial tears are meant to soothe and lubricate our eyes, but in a recent turn of events, BRS Analytical Service, a pharmaceutical testing lab, has issued a voluntary recall of over 75,000 cases of eye care products, including different types of artificial tears. This action comes after a U.S. Food and Drug Administration enforcement report highlighted concerns regarding the quality and safety of these products. AvKare, the distributor of these products, also made a public announcement regarding the recall.
Products Impacted by the Recall
The recall encompasses several lots of five distinct eye care products:
- Artificial Tears Ophthalmic Solution: This specific product includes 13,872 cases with lot numbers and expiry dates of Lot 126 (exp 10/26/25) and Lot 127 (exp 10/30/25).
- Carboxymethylcellulose Sodium Ophthalmic Gel 1%: This product consists of 1,610 cases with varying lot numbers and expiry dates.
- Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%: With 32,876 cases affected, this product has lot numbers and expiry dates of Lot 103 (exp 4/26/25) and Lot 104 (exp 5/03/25).
- Lubricant Eye Drops Solution: This product includes 13,104 cases with lot numbers and expiry dates of Lot 117 (exp 9/20/25) and Lot 118 (exp 9/25/25).
- Polyvinyl Alcohol Ophthalmic Solution 1.4%: This product consists of 14,333 cases with lot numbers and expiry dates of Lot 120 (exp 10/02/25) and Lot 122 (exp 10/09/25).
If you have any of these products, it is crucial to check the lot numbers and expiry dates. If your product matches the affected lots, it is recommended to return it for a refund or dispose of it safely to prevent accidental usage.
Reasons Behind the Recall
The recall was initiated by BRS Analytical Service following an FDA audit that uncovered deviations from Current Good Manufacturing Practice (cGMP). Adhering to cGMP guidelines is essential for ensuring the purity, quality, and safety of pharmaceutical products. These guidelines encompass various aspects of manufacturing, quality control, and product testing to maintain product integrity.
While the specific deviations from cGMP were not detailed in the enforcement report, the FDA cited a “lack of assurance to sterility” as a key reason for the recall. Sterility in this context refers to the absence of biological contaminants, such as bacteria, viruses, or fungi, which could pose serious health risks if introduced into the eyes.
Contaminated eye products can lead to severe infections like conjunctivitis, keratitis, endophthalmitis, and cellulitis, jeopardizing both eye health and overall well-being. Given the vascular nature of the eyes, any microbial intrusion could potentially spread systemically, emphasizing the importance of using sterile eye care products.
In light of this recall, it is crucial for consumers to prioritize eye safety and opt for products that adhere to stringent manufacturing standards. Protecting your vision means safeguarding against potential risks and ensuring that the products you use are held to the highest quality and safety standards.
